Related Experiment Video
Updated: Jun 6, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
NK1 receptor blockade disrupts microtumor growth and aggregation in a three-dimensional murine breast cancer model
Silvia Gutierrez1, M Danilo Boada1
1Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Abstract:
Several data indicate that Substance P (SP) neurokinin type 1 receptor (NK1R) is at the center of the interaction between cancer cells and peripheral sensory neurons. Selecting the appropriate cancer cell line and its susceptibility to being modulated by NK1 antagonists are critical to studying this complex interaction. In the current study, we have focused on this selection by comparing several aspects of the triple-negative breast cancer (TNBC) cell line (MDA-MB-231LUC+) with a modified murine cell line (E0771LUC+), both expressing luciferase. This comparison was made using several methods, SP stimulation and 3D cell culture models, to better reproduce the heterogenous microenvironment of solid tumors observed in vivo. Furthermore, the susceptibility of the murine cell line (E0771LUC+) to NK1R antagonist (Aprepitant) was tested. Our results indicate that E0771LUC+ recapitulates several essential aspects of the human cell line, rendering this murine line ideal to be used on immune-competent animals during in vivo studies. We have also found that both cell lines are susceptible to SP stimulation, and their proliferation is disrupted by NK1R antagonists (Aprepitant). In vivo studies are required to verify and refine these findings.
Insights
Researchers compared triple-negative breast cancer (TNBC) and murine cell lines to study Substance P (SP) and neurokinin type 1 receptor (NK1R) interactions. The murine E0771LUC+ cell line is suitable for in vivo studies and responds to NK1R antagonists.
Area of Science:
- Oncology
- Neuroscience
- Pharmacology
Background:
- Substance P (SP) and its neurokinin type 1 receptor (NK1R) mediate interactions between cancer cells and sensory neurons.
- Understanding this crosstalk is crucial for developing targeted cancer therapies.
- Selecting appropriate cell models is vital for studying NK1R modulation by antagonists.
Purpose of the Study:
- To compare triple-negative breast cancer (TNBC) MDA-MB-231LUC+ and murine E0771LUC+ cell lines for studying SP-NK1R interactions.
- To evaluate the suitability of the murine E0771LUC+ cell line for in vivo research.
- To assess the efficacy of NK1R antagonists on these cell lines.
Main Methods:
- Comparison of MDA-MB-231LUC+ and E0771LUC+ cell lines using SP stimulation and 3D cell culture.
- Assessment of E0771LUC+ cell line's response to the NK1R antagonist Aprepitant.
- Utilized luciferase-expressing cell lines for quantitative analysis.
Main Results:
- The murine E0771LUC+ cell line mirrors key characteristics of the human TNBC MDA-MB-231LUC+ line.
- Both cell lines exhibit susceptibility to SP stimulation.
- NK1R antagonist Aprepitant effectively disrupts the proliferation of both cell lines.
Conclusions:
- The E0771LUC+ murine cell line is a promising model for in vivo studies using immune-competent animals.
- Targeting the SP-NK1R pathway with antagonists like Aprepitant shows potential in disrupting breast cancer cell proliferation.
- Further in vivo validation is necessary to confirm these findings and refine therapeutic strategies.
